A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients with Primary Immune Thrombocytopenia

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

November 17, 2021

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2026

Conditions
Primary Immune Thrombocytopenia
Interventions
BIOLOGICAL

efgartigimod PH20 SC

Subcutaneous injection with efgartigimod PH20 SC

Trial Locations (83)

1714

Investigator site 0470003, Sarpsborg

20007

Investigator site 0010045, Washington D.C.

46804

Investigator Site 0010062, Fort Wayne

50200

Investigator site 0660004, Chiang Mai

52242

Investigator site US0010042, Iowa City

59100

Investigator site 0900017, Tekirdağ

72758

Investigator Site 0010116, Bentonville

73142

Investigator Site 0010095, Oklahoma City

5731191

Investigator site JP0810015, Hirakata

Unknown

Investigator Site 0540001, Buenos Aires

Investigator site 540004, Buenos Aires

Investigator Site 0610012, Garran

Investigator Site 0610003, West Perth

Investigator site 610005, Westmead

Investigator Site 3590017, Plovdiv

Investigator site 0560003, Reñaca

Investigator site 560002, Santiago

Investigator site 0560004, Temuco

Investigator site 860013, Beijing

Investigator Site 0860008, Bengbu

Investigator site 860055, Huizhou

Investigator Site 0860015, Shenzhen

Investigator Site 0860001, Tianjin

Investigator Site 0860010, Wuhan

Investigator Site 0860002, Wuxi

Investigator Site 0860011, Zhengzhou

Investigator site 860058, Zhenjiang

Investigator Site 9950007, Tbilisi

Investigator site 9950009, Tbilisi

Investigator site 9950011, Tbilisi

Investigator site 300008, Athens

Investigator Site 0300009, Thessaloniki

Investigator site 3530003, Dublin

Investigator site 390043, Ferrara

Investigator Site 0390032, Milan

Investigator Site 0390044, Napoli

Investigator site 390041, Napoli

Investigator Site 0810017, Iruma

Investigator Site 0810053, Kanagawa

Investigator Site 0810051, Kitakyushu

Investigator site 810023, Shimotsuke

Investigator Site 0810038, Tama

Investigator site 9620001, Irbid

Investigator site 520002, Aguascalientes

Investigator site 640005, Christchurch

Investigator Site 0480026, Nowy Sącz

Investigator Site 0480037, Skorzewo

Investigator Site 3510007, Lisbon

Investigator site 3510004, Porto

Investigator site 3510001, Vila Nova de Gaia

Investigator Site 0400005, Bucharest

Investigator site 400012, Bucharest

Investigator Site 0400007, Craiova

Investigator site 0070040, Kirov

Investigator Site 0070026, Moscow

Investigator Site 0070038, Nizhny Novgorod

Investigator Site 0070037, Novosibirsk

Investigator site 270003, Johannesburg

Investigator site 270004, Observatory

Investigator site 270001, Pretoria

Investigator site 270002, Randburg

Investigator site 820004, Seoul

Investigator site KO0820007, Seoul

Investigator Site 0660002, Bangkok

Investigator Site 0660003, Bangkok

Investigator site 660005, Bangkok

Investigator Site 0660001, Bangkok Noi

Investigator site TH0660009, Khon Kaen

Investigator site 2610001, Sousse

Investigator site 2160002, Tunis

Investigator Site 0900007, Adapazarı

Investigator Site 0900003, Ankara

Investigator Site 0900008, Ankara

Investigator Site 0900015, Ankara

Investigator site 900004, Izmir

Investigator Site 0900014, Kocaeli

Investigator site 900010, Mersin

Investigator site 900019, Trabzon

Investigator site 440005, Coventry

Investigator site UK044041, London

377-0280

Investigator site 0810016, Shibukawa

40-519

Investigator site PL0480013, Katowice

TR18 2PF

Investigator site UK0440014, Penzance

Sponsors

Lead Sponsor

All Listed Sponsors
lead

argenx

INDUSTRY

NCT04812925 - A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients with Primary Immune Thrombocytopenia | Biotech Hunter | Biotech Hunter